Centro Studi GISED

Go to content
Change language  EN IT


What we do


The PsoReal registry is a program of "outcomes research" on psoriasis in its various forms which originates from the PsoCare project coordinated in Italy by Centro Studi GISED from 2005 to 2010.

The PsoReal program involves:

  • the establishment of a network of reference dermatological centers in different Italian regions;
  • the enrollment of consecutive patients receiving for the first time in their life a new systemic agent with the indication "psoriasis" and/or "psoriatic arthritis" at the participating centers; in addition, to new patients, patients already enrolled in the Psocare registry in the participating centres will be considered;
  • the follow-up of patients enrolled with a regular update on the treatment received, outcome variables, and any adverse event.

The information will be collected by doctors and inserted into a web-based database. The information in the database will be updated every six months.

The following systemic agents will be specifically considered: acitretin, cyclosporine, methotrexate, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, apremilast.


The aim is to collect data on at least 1,500 patients and to follow them up for a minimum period of three years, describing the long-term outcome of different systemic treatments, and the benefits and risks of the medications employed, possibly identifying specific groups of patients at increased risk of adverse outcomes or lack of clinical benefit.

The study started on December 2015 with the participation of 17 centers in the Lombardy and Piedmont regions.


Results of the study were published in the following journals:

Cazzaniga S, Heidemeyer K, Naldi L. Phenotypes of Psoriasis in Patients in Need of Systemic Treatment, and Correlation with Personal Habits, Treatment History and Comorbidities: A Cross-sectional Latent Class Analysis of Data from the Italian PsoReal Registry. Acta Derm Venereol. 2023;103:adv5331.

Heidemeyer K, Cazzaniga S, Dondi L, et al. Variables associated with joint involvement and development of a prediction rule for arthritis in psoriasis patients. An analysis of the Italian PsoReal database. J Am Acad Dermatol. 2023;S0190-9622(23)00500-5.

Cazzaniga S, Heidemeyer K, Dondi L, et al. Prevalence of psoriatic arthritis among patients with psoriasis in Italy. J Eur Acad Dermatol Venereol. 2023;37:e306-e308.

Pezzolo E, Cazzaniga S, Di Leo S, Naldi L. Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real-world clinical experience. J Eur Acad Dermatol Venereol. 2022;36:e534-e537.

Damiani G, Cazzaniga S, Naldi L. Use of fumaric acid derivatives in Italian reference centers for psoriasis. Ital J Dermatol Venerol. 2021;156:36-41.

Back to research project

Centro Studi GISED  P.I. 02274270988 | Terms of use    Privacy    Credits

Back to content | Back to main menu
Facebook Twitter LinkedIn Email